FUDA Cancer Hospital, Jinan University
National Key Clinical Cancer Hospital

Focus on treating cancer for 16 years

FUDA was founded in 2003 by Professor Xu Kecheng, who had been bestowed the highest honor of national health system for his outstanding contributions to cancer patients. Over the past 16 years, FUDA has developed into an academic, high-end and international cancer hospital, regarded as one of the best cancer hospitals in China by many International patients.

In terms of cancer treatments, FUDA has a different view. For late-staged cancer patients, the most important thing is to help patients Live With Cancer: we not only use minimally invasive treatment to eradicate as many cancer cells as we can, but also try to make peace with them, turning cancer into a controllable "chronic disease".

conventional therapies

• Surgery
• radiotherapy
• chemotherapy
• targeted therapy
• chemical ablation
• radioactive stent
• radiofrequency ablation
• traditional Chinese medicine
• percutaneous ethanol injection
• anti-angiogenesis

Minimally Invasive therapies

• Irreversible electroporation (Nano-knife)
• cryosurgery therapy
• vascular interventional therapy
• microsphere interventional therapy
• brachytherapy
• photodynamic therapy
• combined immunotherapy
• microwave ablation
• microwave hyperthermia treatment
• ozone therapy

International anti-cancer concept of CCC+P

3Cs+ P treatment mode is the joint effort of many authoritative experts from Guangzhou Fuda Cancer Research Institute and Guangzhou Cancer Cryosurgery Research Institute. This treatment concept combines the advantages of treatment technologies at home and abroad and comprehensively utilizes CSA (Cryosurgery Ablation) therapy, CVI (Cancer Vascular Intervention) therapy, CIC (Combined Immunotherapy for Cancer) and other latest internationally-recognized techniques. 3Cs+ P is based on patient’s condition and highly individualized. In addition, it is a better choice for patients with tumors that are unresectable, metastatic, recurrent or/and unresponsive to radiotherapy and chemotherapy.

• Tan Youhao, from China, advanced liver cancer, survives for 16 years.
• Gurlin, Danish, advanced pancreatic cancer, survives for 11 years.
• Ms. Luo, from Hong Kong, advanced breast cancer, survives for 10 years.
• 85-year-old Singaporean, advanced prostate cancer, survives for 9 years.